Plain-English translation of NCT07783542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help people with moderate-to-severe hidradenitis suppurativa—a painful skin condition that causes recurrent sores and abscesses. You would receive the medication by injection every 4 weeks for 12 weeks during the first part of the study, then every 12 weeks if the treatment seems to work. Half of participants will receive the real medication, and half will receive a placebo (a dummy treatment) so researchers can fairly compare how well the treatment works.
Hidradenitis suppurativa is a serious skin disease that causes ongoing pain and infection, and many people do not respond well to standard antibiotic treatments. This trial exists to see if this new medication might offer relief to people whose condition has not improved with current options.
You likely qualify if…
You likely don't qualify if…
You would attend a screening visit to confirm you qualify, then enter a 16-week double-blind phase where you receive injections of either the new medication or placebo every 4 weeks. After that, you would enter an open-label maintenance phase lasting several more months, where everyone receives the real medication every 12 weeks. Throughout the study, you would have visits to check how you're responding, monitor for side effects, and have blood tests to measure how the medication moves through your body.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States